Crown Partners announces it has successfully arranged $30 million of senior revolving and term debt for HGS BioScience, a portfolio company of Paine Schwartz Partners. The firm served as exclusive financial advisor to the company in connection with this transaction. In procuring this new financing from a leading US commercial bank, Crown demonstrated how it provides specialized expertise and launch-to-close execution to private equity sponsors in the asset-based finance market. Click the link for the full story: https://lnkd.in/gVNhCeXC Mark Seigel Evan Nadler Justin Anderson Mary C. Jay Diesto, CPA Yzalare Trish Andal, CPA Juno Fragante, CPA, CFA #abl #assetbasedlending #nonbanklender #debtadvisory #capitalmarkets #middlemarket #debt #banking #bankingindustry #liquidity #investmentbanking #privateequity #directlending #privatecredit
Crown Partners’ Post
More Relevant Posts
-
Principal Financial Group Inc. has significantly increased its stake in AGNC Investment Corp., a real estate investment trust, by 44.2% during the first quarter, now holding 58,740 shares valued at $582,000. This move highlights growing confidence in AGNC's performance, which has been positively reviewed by several equity analysts. With institutional investors like Norges Bank and Vaughan Nelson also showing interest, AGNC's market cap stands at $7.09 billion with a promising dividend yield of 14.8%. Are you adding AGNC to your investment portfolio? 💼📈 #RealEstate #Investment #REIT #AGNC #Finance #Stocks
To view or add a comment, sign in
-
Deal news: Goldman Sachs and BNP Paribas bank arms to run $815m refinancing, taking out one of the largest ever Italian private credit deal The transaction is in initial market sounding stage in the high yield market, with the two banks testing appetite for Neopharmed S.p.A., Italian pharmaceutical company. The offering will likely be a split of fixed and floating rate notes given strict Italian regulations on levered loans, reports Bloomberg. In 2022, private equity sponsors Ardian and NB Renaissance took out a unitranche mixing junior and senior debt from private credit lenders including Goldman Sachs Asset Management, Arcmont Asset Management, CVC Capital Partners and Macquarie Group to back their investment in Neopharmed. It’s worth noting that sponsors can generally save a sizable amount through refinancing with syndicated loans by banks to take out the private lenders. For example, KKR had previously refinanced portco April Group’s €1.2bn debt with a 250bps reduction in cost of borrowing. Follow for the latest deal news in private credit and alternative investment. #privatecredit #privateequity #investmentbanking #directlending #investing
To view or add a comment, sign in
-
As we look forward to the New Year, we are recounting highlights from 2024. This year Bancroft Capital’s Investment Banking Team set a high-bar for diverse banks with the successful close of the firm’s first three sole-managed Initial Public Offerings (IPOs). Firm commitment underwritings for Primega Group Holdings Ltd. (Nasdaq: PGHL), Premium Catering Holdings, Ltd. (Nasdaq: PC), and SKK Holdings Ltd (Nasdaq: SKK) raised $7 million, $9.5 million, and $10 million respectively, and represent the earliest of several transactions in the offering pipeline. Eight additional issuers publicly filed for their upcoming IPOs in the third quarter identifying Bancroft as their lead or co-lead underwriter. They include Ten-League International Holdings Limited (TLIH), Fitness Champs Holdings Limited (FCHL), Hong Kong Pharma Digital Technology Holdings Ltd (HKPD), COR3&Co. (Holdings) Ltd (COC), TEN Holdings, Inc. (XHLD), Delixy Holdings Ltd (DLXY), 707 Cayman Holdings Limited (MKR), and Thoughtful Media Group, Inc. (TMGX). #BancroftCapital #2024Achievements #IPOTransactions
To view or add a comment, sign in
-
A Noerr team led by Torsten Wehrhahn and Martina Buller advised an international banking syndicate led by Deutsche Bank on syndicated financing for Medios AG. The credit facilities provided under the loan agreement will be used among other things to refinance existing financial obligations, including bridge financing for the acquisition of Ceban Pharmaceuticals B.V. and general working capital requirements within the group. Press release: https://lnkd.in/eMChW-JM #TeamNoerr Torsten Wehrhahn, Martina Buller and Inken Rüdebusch
To view or add a comment, sign in
-
📊 A Dramatic Rise in Unclaimed Shares & Dividends! 🚀 Here's something to ponder: the value of unclaimed shares and dividends has skyrocketed over the past four years! - **March 2019:** - Unclaimed shares: ₹21,068 Cr - Unclaimed dividends: ₹2,423 Cr - **March 2023:** - Unclaimed shares: ₹47,226 Cr - Unclaimed dividends: ₹5,715 Cr Is your money part of these unclaimed funds? Check it out and take action today! 💡 Source: IEPFA #FinancialLiteracy #UnclaimedFunds #Investment #Finance #LIPL
To view or add a comment, sign in
-
Exploring the Future of Private Assets with Decalia Capital In a rapidly evolving financial landscape, private assets are becoming an increasingly important part of investment portfolios. Rodolfo De Benedetti, Partner & VP of the Board at Decalia Capital, recently shared his insights on the trends shaping this dynamic sector. Key takeaways: Growth in Private Credit: With traditional banks stepping back from lending, private credit is offering attractive risk-return opportunities. Strategic Investment: A balanced approach, combining top-down and bottom-up strategies, is essential for navigating private markets. Alignment is Key: At Decalia, we ensure our interests align with our investors by investing our own capital alongside theirs. It's all about shared success! The future of private assets looks promising, and it's an exciting time to explore the opportunities it offers. #PrivateAssets #InvestmentStrategy #WealthManagement #DecaliaCapital #PrivateCredit
To view or add a comment, sign in
-
Fundraising has slowed as has M&A – S&P Global estimates that global private equity and venture capital volume fell 61% in 2022 versus the prior year and 65% in 2023 versus 2022. Where do you think the 2024 volume will be relative to 2023? As voted by the delegates attending the panel Health Check: Corporate Credit Performance and Alternative Lending Developments with Ruth Yang MD at S&P Global Ratings, Trevor Clark Managing Partner at TPG Twin Brook Capital Partners, Alex Chi Co-Head Americas Direct Lending at Goldman Sachs Asset Management, Timothy Lyne, CEO at Antares Capital LP, Mark Gertzof, Head of Origination at The TCW Group Private Credit and Alan Schrager, Senior Partner and PM at Oak Hill Advisors, L.P. LSTA DealCatalyst #PCDL2024 #Privatecredit #directlending
To view or add a comment, sign in
-
Great first meeting of the LIQID Private Equity Council with Britta Lindhorst, Philipp Klöckner, Florian Heinemann and José Luis González – and these takeaways on the state of private equity in late 2024: 1. The much-discussed exit challenges for existing portfolio companies are likely to ease in 2025 – but actually provide great opportunities for midlife co-investment transactions. Our partner Neuberger Berman is currently seeing fantastic deal flow on mid-sized companies with robust business models and strong operational performance. 2. Concerns that growing capital inflows may depress the long-term returns of private equity are likely overblown: unlike in public equities, the investment universe for private equity is huge. In Germany alone, more than 95% of companies with revenues >€50 million are privately held. Private equity is well-positioned to absorb capital and invest it efficiently – and has so far barely scratched the surface. 3. The S&P 500 may well outperform private equity over certain periods – with 2024 potentially a case in point. But as an illiquid asset class, the performance of private equity should be gauged over periods of at least five years. Over those time frames, top private equity managers have historically outperformed the S&P – and are likely to do so in future. Thank you for your insights and see you soon!
To view or add a comment, sign in
-
In this special report, the Akin Private Equity Team dives into where we think the opportunities to utilize dry powder will be in the market this year. We cover the intensifying scrutiny of regulatory agencies and foreign investment regulation around the activities of PE funds, the demand for further disclosures and reporting around antitrust approval processes, workforce management issues, the fundraising environment, liquidity constraints and dealmaking and the debt financing and fund finance arenas. Our industry experts also provide insight into PE dealmaking within the healthcare & life sciences, technology and energy transition and infrastructure spaces. Our fully integrated deal teams are grateful for the trust our PE clients continue to place in us to help them to deploy capital and to secure exits. Cheers to seizing opportunities together in 2024! #AkinPE
To view or add a comment, sign in
-
💡 Despite lower fundraising than in 2022, 2023 still ended on a high note for public #PE dealmaking, with more deals announced in Q4 than any other quarter. This is largely due to top firms tapping into new forms of #AUM growth such as private wealth channels and insurance capital. Our new public PE report investigates how #GPs are overcoming the current fundraising shortage, takes a pulse check of the top seven alternative managers, and analyzes the strategies your fund manager may be considering. Learn more here: https://lnkd.in/gJFzGr7r
To view or add a comment, sign in
397 followers